Baseline characteristics
| Characteristics | Number of patients |
| Patients enrolled | 28 |
| Age, years | |
| Median | 72 |
| Range | 61–90 |
| Race | |
| Asian | 1 |
| Caucasian | 27 |
| ECOG PS | |
| 0 | 11 |
| 1 | 17 |
| Treatment of the primary | |
| Radical prostatectomy | 11 |
| Radiation therapy | 8 |
| None | 9 |
| Gleason score at diagnosis (n=24) | |
| ≤6 | 1 |
| 7 | 9 |
| ≥8 | 14 |
| Clinical stage at diagnosis (n=17) | |
| T1c | 7 |
| T2b | 6 |
| T2c | 3 |
| T3 | 1 |
| M0 | 5 |
| M1 | 12 |
| Pathological stage (n=11) | |
| T2 | 6 |
| T3 | 5 |
| N0 | 6 |
| N1 | 5 |
| Sites of metastatic disease | |
| Bone only | 13 |
| LNs only | 3 |
| Bone and LN | 9 |
| Lung | 1 |
| Liver | 2 |
| Number with measurable disease | 12 |
| Lesion that could be biopsied | 17 |
| PSA, ng/mL | |
| Median | 26.61 |
| Range | 3.03–2502.75 |
| Hemoglobin, g/dL | |
| Median | 12.9 |
| Range | 8.9–15.1 |
| Alkaline phosphatase, U/L, at enrollment | |
| Median | 71 |
| Range | 35–568 |
| Lactate dehydrogenase, U/L, at enrollment | |
| Median | 213 |
| Range | 144–1432 |
| C reactive protein, mg/L, at enrollment (n=27) | |
| Median | 5.1 |
| Range | <2.9–130 |
| Prior therapies | |
| Docetaxel for castration-sensitive disease | 4 |
| Abiraterone | 10 |
| Enzalutamide | 28 |
| Radium-223 | 1 |
| Sipuleucel-T | 5 |
| Number of weeks on enzalutamide prior to study | |
| Median | 51.9 |
| Range | 22.9–230.3 |
ECOG PS, Eastern cooperative oncology group performance status; LN, lymph node; PSA, prostate-specific antigen.